Therapeutic Drug Monitoring of CarbamazepineDipesh Raj Panday1*, Karishma Rajbhandari Panday2, Madhur Basnet3, Shyam Kafle4, Bhupendra Shah5and GP Rauniar1
- *Corresponding Author:
- Dipesh Raj Panday
Assistant Professor, Department of Clinical Pharmacology and Therapeutics
BP Koirala Institute of Health Sciences (BPKIHS), Nepal
Tel: + 9779862124700
E-mail: [email protected]
Received date: February 02, 2017; Accepted date: February 11, 2017; Published date: February 18, 2017
Citation: Panday DR, Panday KR, Basnet M, Kafle S, Shah B, et al. (2017) Therapeutic Drug Monitoring of Carbamazepine. Int J Neurorehabilitation Eng 4:245. doi:10.4172/2376-0281.1000245
Copyright: © 2016 Panday DR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Carbamazepine is one of the classical antiepileptic drugs, chemically related to the Tricyclic Antidepressants. There are different methods to detect Carbamazepine in plasma i.e. Therapeutic Drug monitoring (TDM). Various studies claim the usefulness of TDM of Carbamazepine but clear-cut guidelines for TDM are still lacking. This article is authors’ endeavour to summarize facts in different publications on TDM of Carbamazepine. Electronic databases MEDLINE/PubMed, Google Scholar, IMSEAR (Index Medicus for South-East Asia Region) and Scopemed were extensively searched with Mesh (Medical Subject Headings) terms “Carbamazepine” AND “drug monitoring” from earliest possible date (1966) to December, 2016. Articles in any language especially those published in recent years were given preference. For non-English articles, Google translation was used and only abstracts were included. Review is mostly centred on toxic effects, poorly adjusted therapies and poor seizure control. Individualization of drug dose with the help of plasma level detection is a must in case of Carbamazepine therapy. TDM helps better outcome by minimizing the risk of under or overdosing due to drug/food interaction or genetic polymorphism of enzymes and transporters involved in the metabolism of Carbamazepine.